In these exceptional circumstances, what we do matters,
more than ever
Since the Coronavirus outbreak began, Grifols has made its expertise in plasma available to health authorities, governments, agencies and society in general. At Grifols, we believe this current and extraordinary situation requires companies to strive more than ever to serve patients and communities.
For weeks, we have been sharing our extensive expertise in plasma that we have acquired over 100 years with many international health agencies. Particularly, we have shared our knowledge in the collection of convalescent plasma and manufacture of hyperimmune globulins from our work with the Ebola outbreak in Liberia. We continue to advance research, support integrated efforts for developing clinical trials with convalescent plasma from recovered patients, and invest in vaccine research and diagnostic solutions.
We know our products are critical for the patients who depend on our treatments. Through these unsettling times, we are diligently working to ensure there is a supply that can reach each and every one in need. Donations are crucial today and our donor centers form a critical infrastructure in many countries.
Now more than ever, we are extremely grateful to those who continue to donate. Thanks to the commitment of our donors and employees we are able to make a difference at such an exceptional time.
Hyperimmune Globulin, high and consistent concentrations of antibodies against SARS-CoV-2 virus
Convalescent plasma from healthy donors who have recovered from COVID-19 can be converted into a potential treatment.
Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.
This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.
Are you a healthcare professional?